lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-19. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
(2026) study the composition of the Quaternary small mammal assemblage from the Araras Ravine at the Lajedo de Soledade site (Rio Grande do Norte, Brazil), providing evidence of similarities with extant faunas from open environments in the Caatinga and Cerrado. A study on the late Pleistocene/early Holocene fauna from the Pikimachay Cave (Peru) is published by Yataco et al. (2026), who interpret the studied site as likely to be a giant ground sloth burrow that was also used by carnivores and/or humans. Hullot et al. (2026) propose a standardized methodological framework for the study of enamel histology in fossil taxa, and apply it to the study of enamel histology and growth of molars of toxodont notoungulates Pleurostylodon modicus, Eurygenium pacegnum, Adinotherium ovinum and Nesodon imbricatus. Von Koenigswald (2026) reviews the morphological diversity of incisors and canines in extant and fossil mammals. Wilson et al. (2026) compare the wear of bilophodont teeth in xenungulates, pyrotheres, fossil and modern tapirs and in extant marsupials, and interpret their findings as suggestive of browsing feeding behaviors of xenungulates and fossil tapirs, as well as of variable diets of different members of Pyrotheria. Evidence of preservation of amino acids in tooth enamel of fossil proboscideans, equids and rhinocerotids dating back as far as 48 million years is presented by Gatti et al. (2026). Herrando-Pérez et al.
=== Layers === The peritoneum is one continuous sheet, forming two layers and a potential space between them: the peritoneal cavity. The outer layer, the parietal peritoneum, is attached to the abdominal wall and the pelvic walls. The tunica vaginalis, the serous membrane covering the male testis, is derived from the vaginal process, an outpouching of the parietal peritoneum. The inner layer, the visceral peritoneum, is wrapped around the visceral organs, located inside the intraperitoneal space for protection. It is thinner than the parietal peritoneum. The mesentery is a double layer of visceral peritoneum that attaches to the gastrointestinal tract. There are often blood vessels, nerves, and other structures between these layers. The space between these two layers is technically outside of the peritoneal sac, and thus not in the peritoneal cavity. The potential space between the parietal and visceral peritoneum is the peritoneal cavity, filled with a small amount (about 50 mL) of slippery serous fluid that allows the two layers to slide freely over each other. The right paracolic gutter is continuous with the right and left subhepatic spaces. The epiploic foramen allows communication between the greater sac and the lesser sac. The peritoneal space in males is closed, while the peritoneal space in females is continuous with the extraperitoneal pelvis through openings of the fallopian tubes, the uterus, and the vagina.
where Q is a relevant activation energy, given in terms of molecular parameters; T is temperature; R is the molar gas constant; and A is approximately a constant. The activation energy Q takes a different value depending on whether the high or low temperature limit is being considered: it changes from a high value QH at low temperatures (in the glassy state) to a low value QL at high temperatures (in the liquid state).
In meteorites and in prebiotic experiments (e.g. Miller–Urey experiment) many more amino acids than the twenty standard amino acids are found, several of which are at higher concentrations than the standard ones. It has been conjectured that if amino acid based life were to arise elsewhere in the universe, no more than 75% of the amino acids would be in common. The most notable anomaly is the lack of aminobutyric acid.
His tenure as president was taken up largely by fundraising activities, and involved travelling around various campuses in South Africa to recruit students and deepen the movement's ideological base. Some of these students censured him for abandoning NUSAS' multi-racial approach; others disapproved of SASO's decision to allow Indian and Coloured students to be members. Biko stepped down from the presidency after a year, insisting that it was necessary for a new leadership to emerge and thus avoid any cult of personality forming around him. SASO decided after a debate to remain non-affiliated with NUSAS, but would nevertheless recognise the larger organisation as the national student body. One of SASO's founding resolutions was to send a representative to each NUSAS conference. In 1970 SASO withdrew its recognition of NUSAS, accusing it of attempting to hinder SASO's growth on various campuses. SASO's split from NUSAS was a traumatic experience for many white liberal youth who had committed themselves to the idea of a multi-racial organisation and felt that their attempts were being rebuffed. The NUSAS leadership regretted the split, but largely refrained from criticising SASO. The government – which regarded multi-racial liberalism as a threat and had banned multi-racial political parties in 1968 – was pleased with SASO's emergence, regarding it as a victory of apartheid thinking.
Sources: en.wikipedia.org
Recent single-molecule tracking experiments in live E. coli showed an ongoing but slower protein synthesis upon treatment with different aminoglycoside drugs. (Spectinomycin, a related but distinct chemical structure class often discussed with aminoglycosides, does not induce mRNA misreading and is generally not bactericidal.)
=== 547th Volksgrenadier Division === The 547th Volksgrenadier Division continued fighting under the 4th Army in Lithuania and, during the following month, retreated with the 4th Army to East Prussia, remaining there until January 1945. The unit was destroyed near Zinten in February 1945. The remnants of the division were distributed among other divisions. The infantry elements were transferred to the 170th Infantry Division.
Doxycycline was patented in 1957 and came into commercial use in 1967. It is on the World Health Organization's List of Essential Medicines. Doxycycline is available as a generic medicine. In 2023, it was the 77th most commonly prescribed medication in the United States, with more than 8 million prescriptions.
=== Antiquity === The presence and diseases of the thyroid have been noted and treated for thousands of years. In 1600 BCE burnt sponge and seaweed (which contain iodine) were used within China for the treatment of goitres, a practice which has developed in many parts of the world. In Ayurvedic medicine, the book Sushruta Samhita written about 1400 BCE described hyperthyroidism, hypothyroidism and goitre. Aristotle and Xenophon in the fifth century BCE describe cases of diffuse toxic goitre. Hippocrates and Plato in the fourth century BCE provided some of the first descriptions of the gland itself, proposing its function as a salivary gland. Pliny the Elder in the first century BCE referred to epidemics of goitre in the Alps and proposed treatment with burnt seaweed, a practice also referred to by Galen in the second century, referred to burnt sponge for the treatment of goitre. The Chinese pharmacology text Shennong Ben Cao Jing, written ca. 200–250, also refers to goitre.
== History == In 1920, a conference held during the 1st World Scout Jamboree at Olympia, London agreed to create a Boy Scouts international bureau. An office was established at 25 Buckingham Palace Road, London and The Boy Scouts Association of the United Kingdom International Commissioner, Hubert S. Martin, was appointed honorary director. The bureau's principal task was to co-ordinate discussions and prepare a second international conference in Paris in 1922. At the 1922 Paris conference, The International Conference of the Boy Scout Movement and its committee were constituted and took over the bureau in London. In 1961, the organisation's conference reconstituted the organisation under the name World Organization of the Scout Movement (WOSM). Its International Conference of the Boy Scout Movement became WOSM's World Scout Conference ("conference"), its Boy Scouts International Committee became WOSM's World Scout Committee ("committee") and its Boy Scouts International Bureau became WOSM's World Scout Bureau ("bureau").
Sources: en.wikipedia.org
=== Burnout prevention and balancing life === After his personal experience with burnout at the peak of his medical career, Maroon developed a strong interest in burnout prevention and living a more balanced life. He conducted extensive research into burnout, burnout prevention, and what constitutes a healthy, balanced, and successful life outside of a professional career. Maroon has given keynote presentations on this subject matter at national and international conferences. In 2017, he published the book Square One: A Simple Guide to a Balanced Life. In 2025, he was the keynote speaker at Focus Forward 2025 for the state of West Virginia, where he spoke on the topic "How to Die Young as Late as Possible." He has also participated in numerous interviews and seminars promoting healthy living and longevity.
=== Synthesis === 3-CMC is commonly synthesized starting from 3-chloropropiophenone. 3-chloropropiophenone is subjected to alpha halogenation using bromine. Subsequently, methylamine acts as a nucleophile and displaces bromide in a nucleophilic substitution to form a racemic product. Cathinones are usually unstable as a freebase, so the product is often treated with HCl or HBr to form a hydrochloride or hydrobromide salt, respectively.
=== Metabolic disorder === People with diabetes were found to have an increased concentration of ketones, the cause of sweet urine smell, derived from the oxidation of non-esterified fatty acids. Exhaled acetone is often used as a biomarker, but its relevance as a sole biomarker for diabetes is ambiguous. Acetone is considered a biomarker in other diseases, such as lung cancer and cystic fibrosis (CF), and reports on acetone and blood glucose have been mixed. Maple syrup urine disease, characterized by a strong maple syrup scent in urine, is found to have higher keto acid levels.
Eventually the funk project broke up, and in 1987 Staley joined Cantrell's band on a full-time basis. Two weeks after the band's formation, they were playing a gig at Washington State University, trying to fill in a 40-minute set with a couple of original songs along with Hanoi Rocks and David Bowie covers. The band played a couple of gigs in clubs around the Pacific Northwest, calling themselves different monikers, including Diamond Lie, the name of Cantrell's previous band, and "Fuck", before eventually adopting the name that Staley's previous band had initially flirted with, Alice in Chains. Staley contacted his former bandmates and asked for permission to use the name. Nick Pollock was not particularly thrilled about it at the time, and thought he should come up with a different name; both he and James Bergstrom ultimately gave Staley their blessing to use the name.
==== Defense and national security ==== While spending on defense and security becomes very important to examine when dealing with a country immersed in an armed conflict, the analysis on this issue is relatively recent. This can be explained because until the beginning of the second half of the nineties, defense and security spending had significant growth. Spending on defense and security includes, on one hand, the means by which the State must have to defend sovereignty and territorial integrity, and on the other, the costs involved in maintaining internal security. Various studies of National Planning suggest that the Colombian State spends a much greater percentage in defense and security than other Latin American countries. Between 1991 and 1996, the estimated value of these resources was $3.7 billion. That amounts to 2.6% of Colombia's GDP, while the average of this expentiure in Latin American countries was 1.7% of GDP. A study carried out by the Stockholm International Peace Research Institute (SIPRI) for the year 2001 shows that, "Colombia ranked 24th in the countries with the largest participation in military spending, out of a total of 116 investigated. The figure for the participation of military expenditures in GDP was 3.8% for Colombia, while in the countries of the American continent the closest figure is that of the United States with 3.1%, followed by Chile with 2.9%, Ecuador with 2.1%, and the rest of countries below 2.0% ". Thus, for the period 1999–2003, defense and security spending was $8,463,611.0 million, equivalent to 10.5% of GDP in 2003.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.